Page 132 - 第10期

第41卷第10期
·1550 · 南 京 医 科 大 学 学 报 2021年10月

cular disease：a systematic review，meta⁃analysis，and net⁃ Evolocumab for early reduction of LDL cholesterol levels
work meta⁃analysis of randomized trials with 94，283 par⁃ in patients with acute coronary syndromes（EVOPACS）
ticipants［J］. Am Heart J，2019，210：18-28 ［J］. J Am Coll Cardiol，2019，74（20）：2452-2462
［16］ STITZIEL N O，WON H H，MORRISON A C，et al. Inacti⁃ ［29］ SZAREK M，WHITE H D，SCHWARTZ G G，et al. Ali⁃
vating mutations in NPC1L1 and protection from coronary rocumab reduces total nonfatal cardiovascular and fatal
heart disease［J］. N Engl J Med，2014，71（22）：2072-2082 events：the ODYSSEY OUTCOMES trial［J］. J Am Coll
［17］ PHAN B A，DAYSPRING T D，TOTH P P. Ezetimibe ther⁃ Cardiol，2019，73（4）：387-396
apy：mechanism of action and clinical update［J］. Vasc ［30］ SZAREK M，STEG P G，DICENSO D，et al. Alirocumab
Health Risk Manag，2012，8：415-427 reduces total hospitalizations and increases days alive
［18］ GIUGLIANO R P，CANNON C P，BLAZING M A，et al. and out of hospital in the ODYSSEY OUTCOMES trial
Benefit of adding ezetimibe to statin therapy on cardiovas⁃ ［J］. Circ Cardiovasc Qual Outcomes，2019，12（11）：
cular outcomes and safety in patients with versus without 005858
diabetes mellitus：results from IMPROVE ⁃ IT（Improved ［31］ STEG P G，SZAREK M，BHATT D L，et al. Effect of ali⁃
Reduction of Outcomes：Vytorin Efficacy International rocumab on mortality after acute coronary syndromes［J］.
Trial）［J］. Circulation，2018，137（15）：1571-1582 Circulation，2019，140（2）：103-112
［19］ OUCHI Y，SASAKI J，ARAI H，et al. Ezetimibe lipid⁃low⁃ ［32］ GENCER B，MACH F，MURPHY S A，et al. Efficacy of
ering trial on prevention of atherosclerotic cardiovascular evolocumab on cardiovascular outcomes in patients with
disease in 75 or older（EWTOPIA 75）：a randomized，con⁃ recent myocardial infarction：a prespecified secondary
trolled trial［J］. Circulation，2019，140（12）：992-1003 analysis from the FOURIER trial［J］. JAMA Cardiol，
［20］ CATAPANO A L，PIRILLO A，NORATA G D. New phar⁃ 2020，15（8）：952-957
macological approaches to target PCSK9［J］. Curr Athero⁃ ［33］ GIUGLIANO R P，MACH F，ZAVITZ K，et al. Cognitive
scler Rep，2020，22（7）：24 function in a randomized trial of evolocumab［J］. N Engl J
［21］ NICHOLLS S J，PURI R，ANDERSON T，et al. Effect of Med，2017，377（7）：633-643
evolocumab on progression of coronary disease in statin⁃ ［34］ ELAMIN A F M，GRAFTON⁃CLARKE C，WEN CHEN
treated patients：the GLAGOV randomized clinical trial K，et al. Potential use of PCSK9 inhibitors as a secondary
［J］. JAMA，2016，316（22）：2373-2384 preventative measure for cardiovascular disease following
［22］ NICHOLLS S J，PURI R，ANDERSON T，et al. Effect of acute coronary syndrome：a UK real⁃world study［J］. Post⁃
evolocumab on coronary plaque composition［J］. J Am grad Med J，2019，95（1120）：61-66
Coll Cardiol，2018，72（17）：2012-2021 ［35］ OLRY D E LABRY LIMA A，GIMENO BALLESTER V，
［23］ CAO Y X，JIN J L，SUN D，et al. Circulating PCSK9 and SIERRA SÁNCHEZ J F，et al. Cost⁃effectiveness and bud⁃
cardiovascular events in FH patients with standard lipid⁃ get impact of treatment with evolocumab versus statins
lowering therapy［J］. J Transl Med，2019，17（1）：367 and ezetimibe for hypercholesterolemia in Spain［J］. Rev
［24］NOZUE T. Lipid lowering therapy and circulating PCSK9 Esp Cardiol，2018，71（12）：1027-1035
concentration［J］. J Atheroscler Thromb，2017，24（9）： ［36］ BLOM D J，RAAL F J，SANTOS R D，et al. Lomitapide
895-907 and mipomersen⁃inhibiting microsomal triglyceride trans⁃
［25］ SCHMIDT A F，PEARCE L S，WILKINS J T，et al. PC⁃ fer protein（MTP）and apoB100 synthesis［J］. Curr Athero⁃
SK9 monoclonal antibodies for the primary and secondary scler Rep，2019，21（12）：48
prevention of cardiovascular disease［J］. Cochrane Data⁃ ［37］ GIAMMANCO A，CEFALÙ A B，NOTO D，et al. Thera⁃
base Syst Rev，2017，4（4）：011748 peutic options for homozygous familial hypercholesterol⁃
［26］ KOREN M J，SABATINE M S，GIUGLIANO R P，et al. emia：the role of lomitapide［J］. Curr Med Chem，2020，27
Long⁃term efficacy and safety of evolocumab in patients （23）：3773-3783
with hypercholesterolemia［J］. J Am Coll Cardiol，2019， ［38］ NOHARA A，OTSUBO Y，YANAGI K，et al. Safety and
74（17）：2132-2146 efficacy of lomitapide in japanese patients with homozy⁃
［27］ HOLLSTEIN T，KASSNER U，GRENKOWITZ T，et al. gous familial hypercholesterolemia（HoFH）：results from
PCSK9 inhibitors in a german single⁃center clinical prac⁃ the AEGR⁃733⁃301 long⁃term extension study［J］. J Ath⁃
tice：real⁃world treatment of patients at high cardiovascu⁃ eroscler Thromb，2019，26（4）：368-377
lar risk over 68 weeks［J］. Am J Cardiovasc Drugs，2021， ［39］ KHOURY E，BRISSON D，ROY N，et al. Review of the
21（1）：83-92 long⁃term safety of lomitapide：a microsomal triglycerides
［28］ KOSKINAS K C，WINDECKER S，PEDRAZZINI G，et al. transfer protein inhibitor for treating homozygous familial